Mutations in specific domains of MT5-MMP prevent the accumulation of toxic APP metabolites and serve as templates for peptide-based therapeutics in human in vitro models of Alzheimer's disease - Aix-Marseille Université Accéder directement au contenu
Pré-Publication, Document De Travail Année : 2024

Mutations in specific domains of MT5-MMP prevent the accumulation of toxic APP metabolites and serve as templates for peptide-based therapeutics in human in vitro models of Alzheimer's disease

Pedro Belio-Mairal
  • Fonction : Auteur
  • PersonId : 1116374
Athina Kamitsou
  • Fonction : Auteur
  • PersonId : 1399511
Delphine Stephan
Nicolas Jullien
Diarra Thiane
  • Fonction : Auteur
  • PersonId : 1399512
Melissa Ramos
  • Fonction : Auteur
  • PersonId : 1399513
Laurence Louis
  • Fonction : Auteur
  • PersonId : 1399514
Florian Benoist
  • Fonction : Auteur
  • PersonId : 1399515
Bastien Serrano
  • Fonction : Auteur
  • PersonId : 1399516
Marion David
  • Fonction : Auteur
  • PersonId : 1399517
Pascaline Lecorché
  • Fonction : Auteur
  • PersonId : 1399518
Emmanuel Nivet

Résumé

In previous work we identified key roles of membrane-type 5-matrix metalloproteinase (MT5-MMP) in Alzheimer’s disease (AD) pathogenesis. More specifically, we uncovered the involvement of the C-terminal domains of the proteinase in the processing of amyloid precursor protein (APP) and the fate of some of its major toxic metabolites (e.g. C99, A). We further described these effects as being dependent on MT5-MMP transmembrane (TM) and intracellular (IC) domains, leading us to hypothesize that modifications in these domains could represent a therapeutic strategy to modulate APP toxic metabolites. To test this, here we generated MT5-MMP variants carrying amino acid deletions or substitutions in entire proteinase domains or in selected amino acid clusters in the IC domain. MT5-MMP variants were co-transfected in human cell lines overexpressing C99, reminiscent of an AD setting. We have identified mutations in the IC domain that induce C99 degradation and a decrease in A levels, while other mutations have divergent effects on these APP metabolites. Furthermore, high content imaging revealed the importance of MT5-MMP IC modifications in C99 subcellular trafficking through the endomembrane system and how this impacts C99 processing. Proximity ligation assays also highlight the importance of the IC domain in MT5-MMP co-localization, and possible interaction, with C99. In a translational effort, we synthetized and a functionalized a peptide mimicking the MT5-MMP IC domain carrying mutations in the N-terminus. We demonstrated that this synthetic peptide efficiently decreased C99 levels in our AD in vitro model. Overall, our study highlights the role of a selected group of amino acids in the C-terminal domains of MT5-MMP as the basis for a better understanding of the proteinase’s contribution to APP metabolism. Moreover, this study provides a new approach for designing peptide-based therapeutic strategies against AD based on the properties of specific MT5-MMP domains to prevent C99 and A accumulation.
Fichier principal
Vignette du fichier
Belio-Mairal et al_2024.pdf (4.13 Mo) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-04642476 , version 1 (10-07-2024)

Identifiants

  • HAL Id : hal-04642476 , version 1

Citer

Pedro Belio-Mairal, Athina Kamitsou, Delphine Stephan, Nicolas Jullien, Diarra Thiane, et al.. Mutations in specific domains of MT5-MMP prevent the accumulation of toxic APP metabolites and serve as templates for peptide-based therapeutics in human in vitro models of Alzheimer's disease. 2024. ⟨hal-04642476⟩
0 Consultations
0 Téléchargements

Partager

Gmail Mastodon Facebook X LinkedIn More